Table 1 Neutralizing antibody titers (Log10 MN₅₀ titers) in marmosets after vaccination during pregnancy

Post-prime (week)	0	2	4	5	5.3	6.3	7
Est. gestation (day±3)	40	47	68	75	77	85	89
ZIKV challenge				0 dpi	2 dpi	9 dpi	14 dpi
ZVC1	0.70	0.70	0.70	0.70	0.70	1.56	3.27
ZVC2	0.70	0.70	0.70	0.70	0.70	3.30	3.72
GMT	0.70	0.70	0.70	0.70	0.70	2.44	3.50
Lower 95% C.I.	0.70	0.70	0.70	0.70	0.70	−8.66	0.65
Upper 95% C.I.	0.70	0.70	0.70	0.70	0.70	13.52	6.35
ZPIV1	0.70	2.11	2.69	3.27	3.53	3.87	3.86
ZPIV2	0.70	2.02	2.58	3.01	3.22	3.87	3.86
ZPIV3	0.70	0.70	3.02	3.42	3.58	4.36	4.73
ZPIV4	0.70	1.11	2.80	3.24	3.17	4.41	5.11
GMT	0.70	1.48	2.77	3.23	3.38	4.12	4.39
Lower 95% C.I.	0.70	0.39	2.47	2.97	3.04	3.65	3.39
Upper 95% C.I.	0.70	2.58	3.07	3.50	3.71	4.60	5.40
p-value		0.287	0.0001	<0.0001	<0.0001	0.0012	0.168

Marmosets were immunized with 2.5 μg alum adjuvanted ZPIV at 0 and 3 weeks or remain unimmunized. Then, all marmosets were bled at week 0 (prior to 1st vaccine), 2, 4 (1-week post-boost), and 5 (2-weeks post-boost) prior to ZIKV challenge, then, 2, 9, and 14 days after challenge. ZVC, unvaccinated, Zika virus infected control, ZPIV, zika purified inactivated virus, C.I., confident interval, GMT, geometric mean. Statistical difference between the ZVC and ZPIV groups was analyzed using ANOVA test. Within the unvaccinated ZVC group, MN₅₀ titers at day 89 were significantly different (P = 0.0318) from the titers at day 77 but not from day 85 (P = 0.2426). Within the vaccinated ZPIV group, MN₅₀ titers at day 77 were not significantly different (P > 0.39) from those at day 85 or day 89.

Quick links

Search